Precision medicine specialist Lucence, with a presence in Suzhou, Hong Kong, and Palo Alto, California, has announced that the interim results of the LIQUIK study, a prospective international multicenter liquid biopsy study for lung cancer, will be reported at the IASLC 2023 World Conference on Lung Cancer (WCLC) held on September 9-12, 2023. The study focuses on two key areas: the detection capabilities of amplifier-based liquid biopsy for lung cancer-related biomarkers and the sensitivity of sequencing techniques targeting free RNA (cfRNA) in plasma for lung cancer detection.
Key Findings from the LIQUIK Study Interim Results
The interim results from the WCLC highlight the concordance of LiquidHALLMARK ctDNA liquid biopsy with tissue-based profiling across 9 NCCN guideline-recommended biomarkers (G9), including EGFR, ALK, RET, ROS1, NTRK fusions, MET, BRAF, ERBB2, and KRAS. The concordance rates ranged from 93.1% to 100%. In a comparison involving 63 patients with tissue-confirmed G9 biomarkers, LiquidHALLMARK® ctDNA-only testing detected 49 G9 biomarkers, outperforming an FDA-approved ctDNA-only liquid biopsy test which detected 42 G9 biomarkers.
Lucence’s cfRNA Expression Level Analysis
The research results demonstrated that Lucence’s cfRNA expression level showed an overall sensitivity of 83.3%, with 77.8% for early lung cancer and 86.7% for advanced lung cancer, and a specificity of 93.8%. These findings underscore the potential of Lucence’s liquid biopsy technology in enhancing the detection and management of lung cancer.-Fineline Info & Tech
